Hodgkin Lymphoma
Introduction And Epidemiology
- Malignant process involving lymphoreticular system.
- Accounts for 6% of all childhood cancers; constitutes 15% of malignancies in adolescents (15-19 years).
- Most common malignancy in adolescent age group.
- Worldwide incidence: 2-4 new cases per 100,000 population annually.
- Exhibits bimodal age distribution: peaks at 15-35 years and >50 years.
- Male predominance observed in young children; gender ratio equalizes beyond 12 years.
- Socioeconomic correlation: Associated with lower socioeconomic status in children <10 years (developing nations); incidence increases with higher socioeconomic status in young adults (developed nations).
- Strong genetic susceptibility: 99-fold increased risk in monozygotic twins; 7-fold increased risk among siblings.
Etiology And Pathogenesis
- Epstein-Barr virus (EBV) strongly implicated in pathogenesis.
- EBV infection confers fourfold higher risk; EBV DNA frequently integrated into tumor genome.
- Expresses viral antigens: Latent membrane proteins 1 and 2 (LMP1, LMP2) possess transforming properties.
- Pathognomonic cellular hallmark: Reed-Sternberg (RS) cell.
- RS cells characterized as large (15-45 μm), binucleated/multilobulated, featuring prominent eosinophilic nucleoli ("owl's eye" appearance).
- Clonal origin from germinal center B cells; typically lose B-cell gene expression/function.
- Constitutive activation of nuclear factor (NF)-κB pathway promotes cell survival.
- RS cells surrounded by dense inflammatory infiltrate (lymphocytes, macrophages, plasma cells, eosinophils).
- Inflammatory cells secrete cytokines (IL-1, IL-6, tumor necrosis factor) promoting disease progression.
Pathological Classification And Immunophenotype
Histologic Variants
World Health Organization classification delineates two distinct disease groups: Classical Hodgkin Lymphoma (cHL) and Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
| Subtype | Histopathologic Characteristics | Clinical Nuances And Frequency |
|---|---|---|
| Nodular Sclerosis cHL | Collagen bands radiating from capsule; numerous lacunar variant RS cells. | Most common subtype in adolescents (74%) and developed nations. |
| Mixed Cellularity cHL | Heterogeneous infiltrate (eosinophils, histiocytes); intact capsule; lacks fibrous bands. | Common in children <10 years (32%); strongly associated with EBV. |
| Lymphocyte-Depleted cHL | Marked reticulin fibrosis; lymphocyte depletion; sheets of pleomorphic RS cells. | Rare; signifies poor prognosis. |
| Lymphocyte-Rich cHL | Rare RS cells; background dominated by small mature lymphocytes; nodular appearance. | Excellent prognosis; closely mimics NLPHL. |
| Nodular Lymphocyte-Predominant | Scattered large neoplastic "popcorn" cells (multilobulated nuclei); lacks classic RS cells. | Localized, non-bulky mediastinal disease; asymptomatic presentation. |
Immunophenotypic Profile
| Cellular Marker | Classical Hodgkin Lymphoma| | Nodular Lymphocyte-Predominant |
|---|---|---|
| CD15 | Positive (70%) | Negative |
| CD30 | Positive (100%) | Negative |
| CD45 (Leukocyte Common Antigen) | Negative | Positive |
| CD20 (B-cell marker) | Negative/Rarely Positive (20-30%) | Positive (100%) |
| Pax5 | Positive | Positive |
Clinical Manifestations
Constitutional Symptoms
- Present in approximately 20-30% of patients.
- Classified as 'B' symptoms; carry significant adverse prognostic value.
- Fever: Unexplained, recurrent temperatures >38°C for >3 days.
- Weight Loss: Unexplained loss exceeding 10% of total body weight over preceding 6 months.
- Night Sweats: Drenching character.
- Note: Pruritus, lethargy, anorexia occur but exclude formal 'B' symptom classification.
Organ-Specific Involvement
- Lymph Nodes: Painless, firm, rubbery cervical or supraclavicular lymphadenopathy (80% primary involvement). Spread occurs contiguously.
- Mediastinum: Present in 75% of adolescents. Manifests as persistent nonproductive cough. Superior vena cava syndrome relatively uncommon.
- Spleen: Enlarged on exam; definitive involvement requires functional imaging confirmation.
- Lungs: Parenchymal lesions from direct mediastinal/hilar extension or discrete nodules. Pleural effusions common.
- Bone Marrow: Causes anemia, neutropenia, thrombocytopenia.
- Bones: Presents with localized bone pain.
Diagnostic Evaluation
- Imaging Modalities: Chest radiograph evaluates mediastinal mass proportion (>1/3 thoracic diameter defines bulk disease). Computed Tomography (CT) of neck, chest, abdomen, pelvis assesses anatomical disease extent.
- Functional Imaging: Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) highly sensitive for staging, quantifying disease, and evaluating therapeutic response.
- Tissue Biopsy: Excisional or core biopsy mandatory. Fine-needle aspiration universally inadequate for architecture evaluation.
- Bone Marrow: Bilateral aspiration and biopsy indicated for advanced stages; may be omitted if PET-CT definitive.
- Laboratory Studies: Complete blood count, erythrocyte sedimentation rate (ESR), ferritin, liver/renal function panels.
Staging Classification
Utilizes Lugano/Ann Arbor criteria for standardized staging.
| Stage | Definition Of Nodal And Extranodal Involvement |
|---|---|
| Stage I | Single lymph node region (I) OR single contiguous extranodal lesion without nodal involvement (IE). |
| Stage II | Two or more nodal groups on same side of diaphragm (II) OR limited contiguous extranodal involvement (IIE). |
| Stage III | Lymph nodes involved on both sides of diaphragm; may include spleen involvement (IIIS) or localized contiguous extralymphatic organ (IIIE). |
| Stage IV | Disseminated, noncontiguous extralymphatic involvement (lung, liver, bone marrow, bone). |
Modifiers:
- A: Asymptomatic.
- B: Presence of 'B' symptoms.
- Bulky (X): Mediastinal mass >1/3 thoracic diameter OR continuous nodal aggregate >6-10 cm.
Prognostic Factors
- Adverse Clinical Features: Advanced stage (III, IV), B symptoms, bulky disease, extranodal extension, male sex.
- Adverse Laboratory Features: Elevated ESR, Hemoglobin <10 g/dL, Leukocytes >11,500/mm³, Albumin <3.5 g/dL.
- Pathologic Features: Abundant CD68+ macrophages, elevated IL-1/IL-6/TNF correlate with unfavorable prognosis.
- Treatment Response: Rapidity of response to initial chemotherapy cycles (measured via FDG-PET Deauville criteria) highly predictive of ultimate outcome.
Management Strategies
Chemotherapy
- Represents primary therapeutic modality; protocols risk-adapted based on stage, bulk, and early therapeutic response.
- Favorable / Low Stage (IA, IIA, no bulk): 2-4 cycles of ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) or OEPA (Vincristine, Etoposide, Prednisone, Doxorubicin). Cure rates 85-90%.
- Unfavorable / Advanced Stage (IIB-IV, bulk, B symptoms): 4-6 cycles of dose-intense multiagent therapy. ABVD, BEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone), or AEPA/CAPDac.
Targeted Therapy And Immunotherapy
- Designed to maximize efficacy while mitigating severe late effects of traditional cytotoxic agents.
- Brentuximab Vedotin: Chimeric anti-CD30 monoclonal antibody linked to antimitotic monomethyl auristatin E. Highly effective for refractory disease; actively incorporated into upfront OEPA/COPDac backbones replacing vincristine.
- Nivolumab And Pembrolizumab: PD-1 checkpoint inhibitors. Block immune evasion pathways, restoring T-cell cytotoxicity.
- Cellular Therapy: Epstein-Barr virus-specific cytotoxic T-lymphocytes (EBV-CTLs) target LMP1/LMP2 antigens in refractory EBV-positive disease. CD30 Chimeric Antigen Receptor (CAR) T-cells under investigation.
Radiation Therapy
- Highly radiosensitive malignancy.
- Utilized as consolidation in combined modality therapy, particularly for bulky disease or slow responders.
- Dosage: 15-25 Gy utilized currently.
- Technique: Transitioned from extensive involved-field radiation to involved-node radiation or proton beam therapy to spare adjacent healthy tissue.
- Current trials aim to completely eliminate radiation in patients demonstrating rapid complete early response (PET-negative) to chemotherapy, mitigating late toxicity risks.
Management Of Relapsed/Refractory Disease
- Most relapses occur within 3 years post-diagnosis.
- Standard Protocol: Myeloablative reinduction chemotherapy followed by autologous stem cell transplantation (SCT).
- Allogeneic SCT: Demonstrates superior reduction in relapse rates compared to autologous SCT, leveraging graft-versus-lymphoma effect.
- Salvage Regimens: Include APE (Cytarabine, Cisplatin, Etoposide), ICE (Ifosfamide, Carboplatin, Etoposide), or Bendamustine combined with Brentuximab.
Late Effects And Complications
Due to exceptional cure rates, mitigating profound long-term morbidity remains paramount. Incidence of severe adverse health conditions exceeds 15% in adult survivors of childhood HL.
- Secondary Malignancies: Risk 7-18 times higher than general population. Acute myeloid leukemia and myelodysplasia linked to alkylating agents and topoisomerase inhibitors (peaks 10-15 years post-therapy). Breast cancer risk markedly elevated in females receiving thoracic radiation.
- Cardiac Toxicity: Cardiomyopathy, congestive heart failure, pericarditis, coronary artery disease. Direct consequence of cumulative anthracycline (doxorubicin) exposure and mediastinal irradiation.
- Thyroid Dysfunction: Primary hypothyroidism highly common following neck radiation (>20 Gy). Requires lifelong thyroid-stimulating hormone surveillance.
- Pulmonary Toxicity: Pulmonary fibrosis associated with bleomycin and thoracic radiation.
- Gonadal Toxicity: Infertility secondary to alkylator exposure or pelvic radiation. Oophoropexy and gonadal shielding mandated during pelvic irradiation.